MK2140-011:A Randomized Open-label Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-na�ve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
